# A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

> **NCT06834360** · PHASE3 · RECRUITING · sponsor: **Sanofi** · enrollment: 210 (estimated)

## Conditions studied

- Chronic Rhinosinusitis With Nasal Polyps

## Interventions

- **DRUG:** Itepekimab (SAR440340)
- **DRUG:** Placebo
- **DRUG:** Mometasone furoate nasal spray (MFNS)

## Key facts

- **NCT ID:** NCT06834360
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-06
- **Primary completion:** 2027-01-08
- **Final completion:** 2027-12-13
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2026-04-24

## Collaborators

- Regeneron Pharmaceuticals

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06834360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06834360, "A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06834360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*